Sirius Neosight Secures €4.4 Million in Funding for Oncology Innovations
Deal News | Feb 04, 2025 | GO CAPITAL SAS
Sirius Neosight, a company focused on isolating circulating tumor cells (CTC) and developing functional tests for predicting therapeutic responses in oncology, has successfully raised €4.4 million in funding. This financial injection was led by GO CAPITAL through its seed fund GOCA3 and DEMETER via the Metropolitan Industrial Seed Fund (FAIM) Lyon/Saint-Etienne, in addition to contributions from Evolem, Crédit Agricole Création, Octalfa, Angel Santé, Better Angle, and business angels specializing in life sciences. This round of funding aims to expedite the development of Sirius Neosight's personalized medicine platform, which seeks to provide targeted and the most effective cancer treatment tailored to each patient.
Sectors
- Life Sciences
- Venture Capital
Geography
- France – Sirius Neosight and its investors, including GO CAPITAL and DEMETER, are based in France, highlighting the geographic focus of the article.
Industry
- Life Sciences – The article discusses Sirius Neosight's involvement in oncology and personalized medicine, highlighting its focus on tumor cell isolation and therapeutic prediction tests, which are core aspects of the life sciences industry.
- Venture Capital – The article involves multiple VC firms and investors, such as GO CAPITAL and DEMETER, indicating significant venture capital activity in the life sciences sector.
Financials
- €4.4 million – The total amount raised by Sirius Neosight in this funding round involving multiple investors.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Sirius Neosight | Target Company | Company | A company specializing in isolating circulating tumor cells (CTC) and developing personalized oncology treatment predictions. |
| GO CAPITAL | Investor | Company | A private equity firm that invests in innovative companies, involved in this funding round via its GOCA3 fund. |
| DEMETER | Investor | Company | An investment firm focused on sustainable and innovative industries, participated through the Metropolitan Industrial Seed Fund. |
| Evolem | Investor | Company | A private equity and venture capital firm participating in this funding round. |
| Crédit Agricole Création | Investor | Company | The venture capital arm of Crédit Agricole, investing in this life sciences innovation. |
| Octalfa | Investor | Company | An investment company focusing on health and biotech sectors. |
| Angel Santé | Investor | Company | A network of business angels specializing in the health sector. |
| Better Angle | Investor | Company | Contributed to the funding round, supports initiatives in the health and biotech fields. |
| Business Angels | Investors | Company | Specialized investors in the life sciences sector contributing to the funding round. |